Itamar Medical

Zoll Medical announced today that it completed its previously announced $538 million acquisition of Itamar Medical (NSDQ:ITMR).

In September, Zoll confirmed its intent to acquire all outstanding shares of Itamar, a developer of non-invasive devices and solutions for the diagnosis of respiratory sleep disorders, at $31 per American Deposiory Share (ADS), a premium of 50.2% over the price of Itamar’s ADS on the Nasdaq market on Sept. 10.

According to a news release, Israel-based Itamar Medical’s ordinary shares will cease to be traded on the TASE market and the company will no longer have reporting obligations under applicable Israeli securities laws.

Chelmsford, Massachusetts-based Zoll said Itamar will operate as a business division within the company, with Itamar’s CEO, Gilad Glick, to lead the division as President.

Itamar’s principal operations in Caesarea, Israel, will continue with no material changes to operations currently…

Zoll Medical announced today that it will acquire Itamar Medical (NSDQ:ITMR) for a total value of approximately $538 million.

Chelmsford, Massachusetts-based Zoll will acquire all outstanding shares of Itamar, a developer of non-invasive devices and solutions for the diagnosis of respiratory sleep disorders, at $31 per American Deposiory Share (ADS), a premium of 50.2% over the price of Itamar’s ADS on the Nasdaq market on Sept. 10.

According to a news release, both companies’ boards approved the deal, which remains subject to approval by shareholders of Itamar, regulatory approvals and other customary closing conditions. The companies expect the transaction to close by the end of 2021 and, once completed, they expect that Itamar’s principal operations will continue at its current location in Caesarea, Israel.

Itamar develops the FDA-cleared WatchPAT home sleep apnea device designed for sleep apnea diagnosis  for patients and healthcare…